Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· March 10, 2026

Moxie Raises $25M Series C to Bring Clinical-Grade Operating Infrastructure to Independent Aesthetic Practices

View original at globenewswire.com
Moxie Raises $25M Series C to Bring Clinical-Grade Operating Infrastructure to Independent Aesthetic Practices BROOKLYN, N.Y., March 10, 2026 (GLOBE NEWSWIRE) -- Moxie, the clinical-grade operating system for aesthetic medicine, today announced a $25 million Series C funding round led by Viewpoint Ventures, with partic…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Moxie helps aesthetic entrepreneurs save 25+ hours each week

    60% confidence
  • Moxie let me stop being a firefighter and start being a CEO. The financial clarity alone changed how I make decisions. Moxie has helped me gain control over my business so my business doesn't have control over me.

    60% confidence
  • The aesthetic practices that thrive long-term aren't the loudest or the busiest. They're the most disciplined. We built Moxie to give independent practice owners the same caliber of operating infrastructure that was previously only available to those backed by institutional capital.

    60% confidence
  • Aesthetic medicine has grown faster than its infrastructure. We have world-class clinicians running practices on spreadsheets and workarounds — and that's a risk to patients, to margins, and to the long-term credibility of the specialty. Clinically-led growth isn't a marketing phrase. It's the operating discipline that separates practices that scale from practices that collapse under their own weight.

    60% confidence
  • Moxie-supported practices save up to 55% on injectables, devices, and supplies with top-tier pharmaceutical, skincare, and manufacturing companies

    60% confidence
  • Moxie-supported practices grow 60% faster than the industry average

    60% confidence
  • Moxie-supported practices achieve 10% higher margins than industry average

    60% confidence
  • Moxie-supported practices save more than $5,000 per month on products and supplies

    60% confidence
  • Up to 30% of new medspas fail within 18 to 24 months

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com